Erratum: Targeted therapy for advanced solid tumors on the basis of molecular profiles: Results from mypathway, an open-label, phase iia multiple basket study(J Clin Oncol. (2018)36:6(536-542) DOI: 10.1200/JCO.2017.75.3780);Targeted therapy for advanced solid tumors on the basis of molecular profiles: Results from mypathway, an open-label, phase IIA multiple basket study

Journal of Clinical Oncology

Volumn 36, Issue 6, 2018, Pages 536-542

  Hainsworth, John D ^a   Meric Bernstam, Funda ^b   Swanton, Charles ^c   Hurwitz, Herbert ^d   Spigel, David R ^a   Sweeney, Christopher ^e   Burris, Howard ^a   Bose, Ron ^f   Yoo, Bongin ^g   Stein, Alisha ^g   Beattie, Mary ^g   Kurzrock, Razelle ^h  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g GENENTECH INC   (United States)

^h UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; PERTUZUMAB; SONIC HEDGEHOG PROTEIN; TRASTUZUMAB; VEMURAFENIB; VISMODEGIB; BRAF PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; APOCRINE CARCINOMA; BILE DUCT CANCER; BLADDER CANCER; CANCER PATIENT; COLON CANCER; COLORECTAL CANCER; CONFERENCE PAPER; FEMALE; GENE OVEREXPRESSION; HEDGEHOG SIGNALING; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY; NON SMALL CELL LUNG CANCER; OPEN STUDY; OVARY CANCER; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; SALIVARY GLAND CANCER; SOLID MALIGNANT NEOPLASM; UTERUS CANCER; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; GENETICS; MIDDLE AGED; MUTATION; NEOPLASM; PROCEDURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ERBB RECEPTORS; FEMALE; HEDGEHOG PROTEINS; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, ERBB-2;

EID: 85041996976     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.18.02263     Document Type: Erratum

References (36)

1. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
3. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011
4. Sekulic A, Migden MR, Lewis K, et al: Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol 72:1021-1026.e8, 2015
5. Cappuzzo F, Bemis L, Varella-Garcia M: HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med 354: 2619-2621, 2006
6. Forbes SA, Tang G, Bindal N, et al: COSMIC (the Catalogue of Somatic Mutations in Cancer): A resource to investigate acquired mutations in human cancer. Nucleic Acids Res 38:D652-D657, 2010 (suppl 1)
7. Masago K, Asato R, Fujita S, et al: Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma. Int J Cancer 124:2744-2749, 2009
8. Masago K, Miura M, Toyama Y, et al: Good clinical response to erlotinib in a patient with anaplastic thyroid carcinoma harboring an epidermal growth factor somatic mutation, L858R, in exon 21. J Clin Oncol 29:e465-e467, 2011
9. Pakneshan S, Salajegheh A, Smith RA, et al: Clinicopathological relevance of BRAF mutations in human cancer. Pathology 45:346-356, 2013
10. Peters S, Michielin O, Zimmermann S: Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. J Clin Oncol 31:e341-e344, 2013
11. Wang XD, Inzunza H, Chang H, et al: Mutations in the hedgehog pathway genes SMO and PTCH1 in human gastric tumors. PLoS One 8: e54415, 2013
12. Xing M, Alzahrani AS, Carson KA, et al: Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 309:1493-1501, 2013
13. Conley BA, Doroshow JH: Molecular analysis for therapy choice: NCI MATCH. Semin Oncol 41: 297-299, 2014
14. Schilsky RL: Implementing personalized cancer care. Nat Rev Clin Oncol 11:432-438, 2014
15. Hyman DM, Puzanov I, Subbiah V, et al: Vemurafenib inmultiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 373:726-736, 2015
16. Hunter DJ,D'Agostino RB Sr: Let's not put all our eggs in one basket. N Engl J Med 373:691-693, 2015
17. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
18. Yasuda H, Kobayashi S, Costa DB: EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol 13:e23-e31, 2012
19. Andre F, Mardis E, Salm M, et al: Prioritizing targets for precision cancer medicine. Ann Oncol 25: 2295-2303, 2014
20. Perjeta (pertuzumab) [prescribing information]. Genentech, South San Francisco, CA; 2016
21. Herceptin (trastuzumab) [prescribing information]. Genentech, South San Francisco, CA; 2016
22. Tarceva (erlotinib) [prescribing information]. Genentech, South San Francisco, CA; 2016
23. Zelboraf (vemurafenib) [prescribing information]. Genentech, South San Francisco, CA; 2016
24. Erivedge (vismodegib) [prescribing information]. Genentech, South San Francisco, CA; 2015
25. Seo AN, Kwak Y, Kim DW, et al: HER2 status in colorectal cancer: Its clinical significance and the relationship between HER2 gene amplification and expression. PLoS One 9:e98528, 2014
26. Sartore-Bianchi A, Trusolino L,Martino C, et al: Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 17:738-746, 2016
27. Richman SD, Southward K, Chambers P, et al: HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: Analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol 238: 562-570, 2016
28. Grothey A, Van Cutsem E, Sobrero A, et al: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303-312, 2013
29. Mayer RJ, Van Cutsem E, Falcone A, et al: Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372:1909-1919, 2015
30. Van Cutsem E, Peeters M, Siena S, et al: Openlabel phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664, 2007
31. Glisson B, Colevas AD, Haddad R, et al: HER2 expression in salivary gland carcinomas: Dependence on histological subtype. Clin Cancer Res 10:944-946, 2004
32. Cornolti G, Ungari M, Morassi ML, et al: Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland. Arch Otolaryngol Head Neck Surg 133:1031-1036, 2007
33. Laé M, Couturier J, Oudard S, et al: Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: Results in 1005 patients. Ann Oncol 21:815-819, 2010
34. Harder J, Waiz O, Otto F, et al: EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol 15:4511-4517, 2009
35. Blay J-Y, Mazieres J, Perol D, et al: Vemurafenib in non-melanoma V600 and non-V600 BRAF mutated cancers: First results of the ACSE trial. Ann Oncol 27:55PD, 2016 (suppl 6)
36. Marchetti A, Felicioni L, Malatesta S, et al: Clinical features and outcome of patients with nonsmall-cell lung cancer harboring BRAF mutations. J Clin Oncol 29:3574-3579, 2011